Svelta Labs Education & Research Journal
Fresh editorial content for peptide research, skincare science, wellbeing categories, Svelta-GPT updates, and research-use product guidance.
Starting Mounjaro: Planning Support Around Everyday Life
Starting Mounjaro involves more than a prescription. Explore the support, follow-up and practical questions that help people plan around everyday life.
Mounjaro Expiry Dates and Storage: Planning Your Supply
Printed expiry and time after first use are different limits. This guide explains how to check a Mounjaro supply without relying on old forum batch dates.
GLP-1 Medicines and Eating Behaviour: Why Responses May Differ
A 92-person observational study linked external eating scores with weight change. It does not prove that emotional eaters cannot benefit from GLP-1 medicines.
Weight Regain After Stopping GLP-1 Medicines: Evidence and Support
Experiences after stopping GLP-1 medicines vary. Clinical withdrawal studies show why weight maintenance needs continuing support rather than blame.
Mounjaro KwikPen “Golden Dose”: New Pens and Leftover Medicine
A modified Mounjaro KwikPen can look different, but both versions deliver four fixed doses. Leftover solution is not a validated extra dose.
BRP Peptide and Appetite: What Stanford’s Animal Research Found
Stanford’s BRP discovery links computational peptide screening with appetite research in animals. It does not yet establish human benefit or comparative safety.
Intermittent Fasting and the Gut Microbiome: A Brain–Gut Study
A small study tracked gut bacteria and brain activity during intermittent energy restriction. Its associations raise questions rather than establish a fasting prescription.
Wegovy Tablets UK Approval: Oral Semaglutide and Access
Wegovy tablets received UK authorisation in June 2026. Regulatory approval, actual supply and NHS funding are separate steps.
Obesity Prevention and the Food Environment: England’s Policy Debate
Food environments shape the choices available to people. This editorial examines Parliament’s proposed action on healthier sales, advertising and local access.
GLP-1 Side Effects: Common Symptoms and Important Safety Signals
Digestive symptoms are common with GLP-1 medicines, but some warnings are medicine-specific. Here is how to distinguish established risks from online anecdotes.
GLP-1 Medicines and Fat Graft Survival: What the Biology Suggests
A scoping review raises questions about incretin medicines and fat graft biology. Its mechanisms are hypotheses, not proof of poorer surgical outcomes.
FDA Peptide Panel Recommendations: What a Vote Can Change
Reports of favourable peptide-panel votes raised questions about access. The key distinction is between advisory recommendations, agency action and product approval.
